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Ovarian cancer comprises approximately 4% of all new cases of
cancer in women in North America and Western Europe. It is the
most frequent cause of death among patients with gynaecological
malignancies. Most patients are middle aged (40–70 years old) at
the time of diagnosis (Ozols et al, 1992). Owing to the lack of clin-
ical symptoms, primary ovarian carcinoma is often discovered in
an advanced stage when the disease has spread beyond the ovaries
throughout the peritoneal cavity.
At present, treatment of ovarian cancer consists of debulking
surgery followed by platinum-based chemotherapy. Although the
initial response to chemotherapy is high, the majority of patients
with advanced-stage ovarian carcinoma develop residual or recur-
rent disease and approximately 70% of patients die within 5 years
(Ozols et al, 1992).
The main diagnostic tests available to detect the presence of
primary and residual or recurrent ovarian carcinoma are the serum
marker assay CA125, physical examination, ultrasonography
(US), computerized tomography (CT) and magnetic resonance
imaging (MRI) (Morgan et al, 1992). However, these non-invasive
techniques are unsatisfactory for a number of reasons. These
methods cannot reliably detect small tumour deposits, diffuse peri-
toneal carcinosis or tumour in normal sized lymph nodes, all of
which are primary modes of spread of ovarian cancer. Thus, the
definitive diagnosis of primary ovarian carcinoma as well as the
extent of recurrent or residual disease is usually determined at
surgical re-exploration (second-look surgery) (Potter et al, 1980;
Copeland et al, 1994). However, even a careful laparotomy may
not detect all intra-abdominal disease present and cannot be used
to evaluate extra-abdominal disease.
Furthermore, although about 50% of patients undergoing
second-look are disease-free, about 60% of patients with a nega-
tive second look will have a recurrence in the peritoneal cavity
(Cresman and Eddy, 1989; Podratz and Kinney, 1993). This
suggests that non-detectable residual disease is present in the peri-
toneal cavity or retroperitoneal spaces at the time of second-look
surgery (Gershenson et al, 1985), the sensitivity of which ranges
from 76% to 88% (Rubin et al, 1991).
There is therefore a pressing need for a non-invasive test to
detect the presence and determine the location and extent of occult
disease. Such information would guide the surgeon during second-
look laparotomy, whereas laparotomy could be avoided if the
diagnostic test was negative.
After the development of monoclonal antibodies (mAbs) to
tumour-associated antigens, immunoscintigraphy (ISG) has also
been applied for the diagnosis and therapy of ovarian cancer
(Rubin, 1993; Method et al, 1996). Moreover the recent develop-
ment of multi-step procedures, in which the tumour is pretargeted,
and the antibody and label are administered separately, has
allowed background activity to be reduced, the tumour to normal
tissue ratio to be increased, and ISG sensitivity to be improved
(Crippa et al, 1991; Paganelli et al, 1991; Grana et al, 1996).
We have developed a three-step method, involving the
avidin–biotin system, to target radioactive labels to mAbs already
localized onto the tumour. Preclinical and clinical studies showed
that multi-step avidin–biotin methods result in improved local-
ization of radionuclides to tumours compared to the more
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three steps we used are as follows: (i) tumour pretargeting by
biotinylated anti-tumour mAbs; (ii) ‘avidinization’ of the bio-
tinylated tumour-bound mAbs by administration of a molar excess
of avidin; (iii) targeting the tumour by a fast clearing radioactive
biotin derivative.
Numerous mAbs against ovarian cancer have been selected and
characterized, such as the MOv18 mAb, which is expressed on the
cell membrane of about 90% of human ovarian carcinomas (Grana
et al, 1996) and exhibits a very restricted pattern of tissue distribu-
tion (Miotti et al, 1987; Mezzanzanica et al, 1988; Casalini et al,
1997), and the B72.3 mAb, which has been shown to have selec-
tive reactivity for a wide range of carcinomas, including ovarian
cancer (Colcher et al, 1987). As the use of a cocktail of antibodies
has been reported to increase the sensitivity of the method (Matzku
et al, 1989), we used an association of MOv18 and B72.3 mAbs in
this study.
The aim of this study was to evaluate the three-step pretargeting
protocol in the diagnosis of residual or recurrent ovarian carci-
noma. ISG was applied to evaluate the potential of this method to
assess: (a) the absence/presence of residual tumour prior second-
look laparotomy and (b) the potential of ISG in guiding the
surgeon during second look.
MATERIALS AND METHODS
Patients
Thirty patients (38–78 years of age; mean 56.1), all with histo-
logically confirmed ovarian cancer after primary surgery and
chemotherapy treatment were enrolled in the study that was
approved by the Ethical Committees of Scientific Institute HS
Raffaele and European Institute of Oncology. Prior to study entry,
all patients gave written informed consent.
Patients with a life expectancy less than 6 months or with renal
or hepatic failure were excluded from the study. Twenty-eight
patients were at stage III and two patients were at stage IV of the
FIGO classification (20 G3 stage tumours and 11 G2 stage
tumours). Histotype was serous in 17 patients, endometroid in
seven, mucinous in two, clear cell in two and undifferentiated in
two.
At the time of ISG, the serum marker CA125 was elevated in
nine patients, normal in 17 patients and borderline in four.
Five patients had a positive CT/US scan, 12 patients were nega-
tive for the presence of neoplasia, whereas seven patients were
doubtful on CT scan or US; in six patients imaging examinations
were not performed.
All patients underwent second look within 1 week of ISG (mean
3 days). At surgery, samples from peritoneal tissues were taken.
The mean number of biopsies/patient was 16 (range 5–35), taking
care to sample areas which were positive at ISG.
Reagents
Monoclonal antibody MOv18 (IgG1 subclass), which reacts with
the most ovarian carcinomas, and B72.3 (IgG1 subclass), which
recognizes a high molecular weight glycoprotein expressed by
ovarian cancer cells, have been extensively described (Crippa et al,
1991; Larson et al, 1991). The biotinylation of mAbs has also been
described (Magnani et al, 1996). Pure hen egg avidin and strepta-
vidin were obtained from Società Prodotti Antibiotici (Milan,
Italy). DTPA-conjugated biotin was purchased from Sigma (St
Louis, MO, USA).
Radiolabelling
DTPA-conjugated biotin was diluted in phosphate-buffered saline
(PBS), pH 7.4, at a concentration of 2 mg ml–1. The solution was
sterilized by 0.22-mm Millipore filtration. 111InCl3 was diluted in
citrate buffer (0.02 M; pH 6.5) to 740 kBq ml–1. The reagents were
then mixed and allowed to react at room temperature for 10 min.
More than 98% of 111In was bound to the conjugate, as shown by
paper chromatography performed with Whatman no. 1 and bicar-
bonate buffer 0.05 M as liquid phase. The ability to bind avidin
after labelling was verified by FPLC (Pharmacia, Sweden), by
mixing  111In-biotin with an appropriate amount of avidin. No loss
of reactivity was observed.
Toxicity and immunogenicity
All patients were closely observed for 2 h following administra-
tion of avidin. Blood samples (10 ml) were obtained in appropriate
tubes just before the administration of avidin, and 20–25 days after
the injection. All samples were sent for routine blood tests and to
assess the human anti-mouse immunoglobulin (HAMA) and anti-
avidin response (HAAR).
The induction of NAMA antibodies was investigated using an
enzyme-linked immunosorbent assay (ELISA) system (Seccamani
et al, 1989) in 15 patients. In these patients, avidin immuno-
genicity was studied on microwell plates coated with avidin or
streptavidin separately. The plates were saturated for 1 h with
PBS-3% bovine serum albumin (BSA). Diluted human serum was
added and incubated for 1 h at 37°C. After five washes, the
binding of human anti-avidin antibodies was revealed with horse-
radish peroxidase-conjugated rabbit anti-human Ig antibodies
(Dako) diluted 1:1000 for 45 min at 37°C. After six washes, the
enzymatic reaction was developed with a chromogenic substrate
(O-phenylenediamine; Sorin Biomedica, Saluggia, Italy) for 
10 min and blocked by addition of 1 M H2SO4. The optical density
reading was 492 nm.
ISG study
The three-step protocol used has been previously described (Grana
et al, 1996). Briefly, in 15 patients, 1 mg of biotinylated mAb
MOv18 was injected intravenously (i.v.) over 2 min (first step).
After 24–36 h, 1 mg of unlabelled avidin was injected i.v. over 
2 min followed by an additional 5 mg of streptavidin 15 min later
(second step). The aims of these two avidin administrations were,
respectively, to precipitate circulating biotinylated antibodies 
(1 mg) and subsequently to target the biotinylated MAbs bound on
tumour cells (5 mg).
In 15 patients, 1 mg of biotinylated mAb MOv18 plus 1 mg of
biotinylated B72.3 were injected i.v. over 2 min (first step). After
24–36 h, 2 mg of unlabelled avidin was injected i.v. over 2 min,
followed by additional 5 mg of streptavidin 15 min later (second
step).
In all patients, 200 mg of 111In-biotin (111–185 MBq) was
injected i.v. 24 h after administration of the cold avidin in 3 ml of
saline solution in a bolus injection (third step).
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(SPECT) studies (64 ´ 64 pixel matrix, 64 projections over 360°)
of the thorax, abdomen and whole body were performed. Imaging
was performed shortly (1–3 h) after injection of the radiolabel, as
background radioactivity levels were low, due to the three-step
technique employed and fast elimination of the small labelled
biotin molecule.
Images were obtained using rotating gamma-cameras (7500
Orbiter Siemens and Starcam 400 GE), equipped with medium
energy collimators and by selecting two 15% energy windows
centred over the 173 and 247 keV photopeaks of 111In.
Tomographic images were reconstructed using a filtered back
projection algorithm and Hann filter (cut-off 0.5 pixel–1). Planar
and tomographic images were evaluated for the presence or
absence of pathological tracer accumulation by two independent
observers who were unaware of the clinical problem and biochem-
ical tumour marker levels. In case of disagreement, the images
were reviewed by a third reader. ISG results were classified as
true-positive (TP), true-negative (TN), false-positive (FP) and
false-negative (FN) according to the histological diagnosis.
RESULTS
No toxicity was observed after reagent administration. Of the 15
patients tested, two (13%) developed an antibody response to
mouse immunoglobulins, whereas four (27%) patients demon-
strated anti-avidin and five (33%) patients anti-streptavidin anti-
bodies. There was 100% agreement in the evaluation of ISG
results between the two observers. The results are summarized in
Table 1.
There were no differences in results between the two groups of
patients receiving only one kind of antibody or the cocktail of two
antibodies: in fact neither in the group who received one antibody
nor in the other patients did we observe any FN results. Moreover,
in the group of patients with the cocktail of mAbs we observed a
smaller number of FPs than in the other group.
Pathological tracer accumulation was observed by ISG in 25
(83%) of 30 patients; in 21 patients second-look surgery
confirmed the presence of recurrent tumour: 19 had microscopic
disease whereas two had gross macroscopic tumour. In the nine
patients with negative histopathological findings, ISG was
correctly negative in five patients. According to these data, the
results were as follows: 21 TP, five TN and four FP; none was FN.
See Figures 1 and 2 as examples of three-step ISG.
CA125 serum level indicated the presence of a recurrent ovarian
carcinoma in nine (29%) patients, all recognized as TP by ISG. In
four (13%) patients a borderline CA125 serum level was associ-
ated with one TN and three TP results, whereas the 17 (57%)
normal CA125 serum levels consisted of four TN, nine TP and
four FP.
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Table 1 Patient data and results
Patient no. Age Stage CA125 US/CT ISG mAb
1 58 IIIC 3.0 N TN Mov18
2 48 IIIB 2.5 N TN Mov18
3 60 IIIC 18.0 NP TP Mov18
4 60 IIIC 33.0 N TP Mov18
5 38 IV 35.0 N TP Mov18
6 61 IIIC 1.9 NP TN Mov18
7 62 IIIC 27.0 NP TP Mov18
8 65 IIIC 25.0 NP FP Mov18
9 55 IIIC 6.6 N FP Mov18
10 53 IIIB 34.0 NP TN Mov18
11 78 IIIC 35.0 D TP Mov18
12 51 IIIC 27.0 N TP Mov18
13 43 IIIC 25.0 NP TP Mov18
14 64 IIIC 22.0 N TP Mov18
15 61 IV 10.0 N FP Mov18
16 44 IIIC 11.0 P TP Mov18 + B72.3
17 59 IIIA 620.0 D TP Mov18 + B72.3
18 47 IIIC 4.9 P TP Mov18 + B72.3
19 70 IIIC 169.0 D TP Mov18 + B72.3
20 48 IIIB 530.0 P TP Mov18 + B72.3
21 56 IIIC 300.0 P TP Mov18 + B72.3
22 57 IIIC 4.0 N FP Mov18 + B72.3
23 50 IIIC 7.8 D TP Mov18 + B72.3
24 43 IIIB 18.0 D TP Mov18 + B72.3
25 66 IIIC 6.9 N TN Mov18 + B72.3
26 53 IIIC 239.0 N TP Mov18 + B72.3
27 53 IIIC 93.0 D TP Mov18 + B72.3
28 66 IIIC 52.0 D TP Mov18 + B72.3
29 54 IIIC 73.0 P TP Mov18 + B72.3
30 53 IIIC 1200.0 N TP Mov18 + B72.3
FP: false-positive; TN: true-negative; TP: true-positive; N: negative; P:
positive; D: doubtful; NP: not performed. CA125 range: 0–35 m ml–1.
A
B
Figure 1 (A) ISG study (transaxial slices) of patient no. 18 (LM, 48 years
old, IEO); (B) pathological tracer uptake is clearly evident into the whole
abdomen, particularly in mesogastrium, representative of peritoneal
carcinosis. These data were then confirmed during the second-lookCT/US scan indicated the presence of recurrent disease in five
(16%) patients, all of whom were TP. All the seven (23%) doubtful
CT cases turned out to be TP by ISG. Among 12 (39%) patients in
whom CT/US examination did not reveal the presence of recurrent
disease, three were TN, six were TP and three were FP.
Combining the CA125 serum level and the CT/US information,
a correct diagnosis was obtained in 17 (57%) patients, whereas 13
(42%) patients were erroneously evaluated. These 13 patients
consisted of 12 TP and one TN by ISG.
Combining the CA125 serum level and the ISG information, a
correct diagnosis was obtained in 26 (84%) patients (21 TP and
five TN), whereas four (13%) patients were FP (Table 2).
The diagnostic accuracy, positive predictive value and negative
predictive value of ISG were 87%, 84% and 100% respectively.
DISCUSSION
Due to lack of clinical symptoms, primary ovarian carcinoma is
often discovered at an advanced stage when disease has spread
beyond the ovaries to the peritoneal cavity and other organs. For
this reason first laparotomy is not only important therapeutically
but also prognostically. In all the more advanced stages of ovarian
carcinoma, chemotherapy is a standard adjuvant to surgical treat-
ment.
Combined physical examination, serum CA125 assay and CT
scan of the abdomen and pelvis is used to assess disease status in
patients who respond to primary cytoreductive surgery and adju-
vant chemotherapy. Unfortunately, the accuracy of these non-
surgical techniques in detecting persistent or recurrent disease is
poor; and the extent of recurrent or residual disease is generally
determined by surgical re-exploration. Such second-look explo-
ration is useful for determining the efficacy of treatment, identi-
fying additional sites of recurrence and planning additional
therapy and tumour debulking.
Immunoscintigraphy promises to provide more reliable non-
invasive detection and localization of persistent or recurrent
tumour. Recent studies (Lown et al, 1995) reported that the tech-
nique has sensitivity of 72% and 71% in detecting suspected recur-
rence and carcinomatosis respectively. However, after injection of
directly labelled mAb, image interpretation is often difficult
because of non-specific bone marrow, vascular and liver activity
uptake (Crippa et al, 1991). For example, a limitation of 111In-anti-
body scanning is its insensitivity to subphrenic, perihepatic and
perisplenic peritoneal tumour because physiological uptake of
111In-mAb by the liver and spleen obscures findings from adjacent
peritoneal tumour. In carcinoembryonic antigen (CEA)-positive
tumours, gliomas, lung cancers and neuroendocrine tumours, a
new ISG method involving the avidin–biotin pretargeting
approach (Colombo et al, 1993; Dosio et al, 1994; Paganelli et al,
1994) has provided good results, attributable in part to the absence
of physiological hepatic and splenic uptake, as well as with the use
of bispecific mAb, as Peltier stated in his work (Peltier et al, 1993).
Important advantages of the pretargeting/ISG approach are that
circulating antibodies are quickly removed by avidin in the second
step, while the radiolabelled biotin, that is administered subse-
quently, either binds to the tumour-bound antibody or is eliminated
quickly. This allows images with low background activity to be
obtained. Use of the SPECT technique further improves ability to
detect small quantities of residual disease.
We employed this pretargeting approach in 30 ovarian carci-
noma patients enrolled for second-look exploration. We used mAb
MOv18, which is expressed on the cell membrane of about 90% of
ovarian carcinomas. In addition, since the second and third step of
the three-step protocol can be common to all protocols, other
potentially useful mAbs can be injected in sequence or in combi-
nation as the first step, and in fact we injected the cocktail of
MOv18 and B72.3 mAbs in 15 of these patients.
We did not find any significant differences in the two groups of
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Figure 2 ISG performed in patient no. 25 (PA, 66 years old, IEO). This patient was treated with surgery for stage IIIC ovarian carcinoma, followed by
chemotherapy, then underwent ISG; in these images (A: transaxial slices) there is no evidence of pathological uptake of the tracer (B). This negative result was
then confirmed at surgery
Table 2 CA125 serum level and ISG comparison
ISG P ISG N
CA125 P 9 (TP) 0
CA125 N 9 (TP); 4 (FP) 5 (TN)
CA125 D 3 (TP) 1 (TN)
FP: false-positive; TN: true-negative; TP: true-positive. CA125 range: 
0–35 m ml–1.620 P Magnani et al
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patients; however, we think that the administration of a cocktail of
antibodies could result in a targeting of a higher number of tumour
cells and in an increased sensitivity of the method, despite loss of
specificity. This could increase the number of FP but avoid the FN.
Comparison of our ISG results with the second-look biopsy
findings showed that ISG gave 21 TP, five TN and four FP, so that
overall diagnostic accuracy was 87%. The relatively high number
of FP (13%) is probably attributable to the presence of inflamma-
tory tissue, where there is an aspecific uptake due to the inflamma-
tory process itself. All the 13 patients with FN result by combined
CA125 and CT/US were correctly diagnosed by ISG. It is also
noteworthy that for the series as a whole, the ISG technique had a
particularly high negative predictive value.
We conclude, therefore, that ISG can improve the sensitivity of
second-look surgery (particularly laparoscopy), as the surgeon can
direct his attention to, and sample sites of, tracer accumulation
revealed by the ISG procedure. Note that although laparotomy is
currently considered the best method for evaluating ovarian recur-
rences, its sensitivity is in the range 76–88% (Paganelli et al,
1991). Our results also suggest that a negative ISG result, associ-
ated with low CA125 serum levels and negative CT/US findings,
can be interpreted as real absence of recurrent disease, thus
reducing the need for second-look laparotomy.
If these findings are confirmed in a larger number of patients,
we expect ISG to be introduced as a cost-effective procedure in the
follow-up of patients who have received surgery for ovarian carci-
noma, since it promises to reliably identify patients who do not
require second-look laparotomies, and guide biopsies when they
are indicated. We believe our results justify a randomized clinical
trial to compare survival in patients who undergo second-look
laparotomy alone with survival in patients who undergo ISG
guided second-look laparotomy.
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